ZA201902108B - Methods for the treatment of abnormal involuntary movement disorders - Google Patents
Methods for the treatment of abnormal involuntary movement disordersInfo
- Publication number
- ZA201902108B ZA201902108B ZA2019/02108A ZA201902108A ZA201902108B ZA 201902108 B ZA201902108 B ZA 201902108B ZA 2019/02108 A ZA2019/02108 A ZA 2019/02108A ZA 201902108 A ZA201902108 A ZA 201902108A ZA 201902108 B ZA201902108 B ZA 201902108B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- methods
- movement disorders
- involuntary movement
- abnormal involuntary
- Prior art date
Links
- 208000024453 abnormal involuntary movement Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Prostheses (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562129616P | 2015-03-06 | 2015-03-06 | |
US201562175112P | 2015-06-12 | 2015-06-12 | |
US201562180012P | 2015-06-15 | 2015-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201902108B true ZA201902108B (en) | 2021-09-29 |
Family
ID=55590145
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2017/06131A ZA201706131B (en) | 2015-03-06 | 2017-09-08 | Methods for the treatment of abnormal involuntary movement disorders |
ZA2019/02108A ZA201902108B (en) | 2015-03-06 | 2019-04-04 | Methods for the treatment of abnormal involuntary movement disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2017/06131A ZA201706131B (en) | 2015-03-06 | 2017-09-08 | Methods for the treatment of abnormal involuntary movement disorders |
Country Status (23)
Country | Link |
---|---|
US (8) | US20160287574A1 (en) |
EP (2) | EP3265085B1 (en) |
JP (3) | JP6932641B2 (en) |
KR (4) | KR102335744B1 (en) |
CN (4) | CN107624067A (en) |
AU (2) | AU2016229949B2 (en) |
CA (2) | CA2978006C (en) |
CL (1) | CL2017002223A1 (en) |
DK (1) | DK3265085T3 (en) |
EA (1) | EA201791977A1 (en) |
ES (1) | ES2927262T3 (en) |
HK (2) | HK1248609A1 (en) |
HR (1) | HRP20221106T1 (en) |
HU (1) | HUE059747T2 (en) |
IL (3) | IL305352A (en) |
LT (1) | LT3265085T (en) |
MX (2) | MX2017011459A (en) |
PL (1) | PL3265085T3 (en) |
PT (1) | PT3265085T (en) |
RS (1) | RS63647B1 (en) |
SG (1) | SG11201706959TA (en) |
WO (1) | WO2016144901A1 (en) |
ZA (2) | ZA201706131B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014047167A1 (en) | 2012-09-18 | 2014-03-27 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
CN107624067A (en) | 2015-03-06 | 2018-01-23 | 奥斯拜客斯制药有限公司 | Method for treating Abnormal involuntary movement obstacle |
RS65154B1 (en) | 2015-10-30 | 2024-02-29 | Neurocrine Biosciences Inc | Valbenazine dihydrochloride salts and polymorphs thereof |
CN108925135A (en) | 2015-12-23 | 2018-11-30 | 纽罗克里生物科学有限公司 | Prepare (S)-(2R, 3R, 11bR) -3- isobutyl group -9,10- dimethoxy -2,3,4,6,7,11b- hexahydro -1H- pyrido [2,1-a] isoquinolin-2-yl 2- amino -3 Methylbutanoic acid ester two (4- toluenesulfonate) synthetic method |
WO2017221169A1 (en) * | 2016-06-24 | 2017-12-28 | Lupin Limited | Premixes of deutetrabenazine |
EA201991786A1 (en) | 2017-01-27 | 2020-01-16 | Нейрокрин Байосайенсиз, Инк. | METHODS FOR INTRODUCING SOME VMAT2 INHIBITORS |
EA201992168A1 (en) | 2017-03-15 | 2020-03-16 | Ауспекс Фармасьютикалз, Инк. | ANALOGUES OF DEUTETRABENAZINE, THEIR PRODUCTION AND APPLICATION |
US20200179352A1 (en) * | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
AU2018366039A1 (en) * | 2017-11-08 | 2020-05-14 | Wen-Yen Huang | Esters of Dihydrotetrabenazine |
US20200345663A1 (en) * | 2018-06-10 | 2020-11-05 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
AU2019284477B2 (en) * | 2018-06-10 | 2022-08-11 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
US20190374521A1 (en) * | 2018-06-10 | 2019-12-12 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
CA3104693A1 (en) | 2018-08-15 | 2020-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
CN113395966A (en) * | 2018-12-13 | 2021-09-14 | 奥斯佩克斯医药公司 | Method for treating dyskinesia in cerebral palsy |
CN109793745B (en) * | 2019-01-24 | 2021-05-25 | 遵义医科大学 | Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
TW202128164A (en) * | 2019-10-22 | 2021-08-01 | 美商神經治療有限責任公司 | Tetrabenazine transdermal delivery device |
IL307680A (en) * | 2021-04-15 | 2023-12-01 | Neurocrine Biosciences Inc | Methods for the combined administration of deutetrabenazine and a cyp2d6 inhibitor |
US20240197714A1 (en) * | 2021-04-15 | 2024-06-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
WO2024166115A1 (en) | 2023-02-10 | 2024-08-15 | Teva Pharmaceutical Industries Ltd. | Movement disorder detection and assessment |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2843591A (en) | 1958-07-15 | Method for preparing same | ||
US2830993A (en) | 1958-04-15 | Quinolizine derivatives | ||
US3045021A (en) | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
HU175890B (en) | 1977-06-15 | 1980-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new 1,2,3,4,6,7-hexahydro-11-b-alpha-benzo-square bracket-a-square brecket closed-quinolyzine derivatives |
US4543370A (en) | 1979-11-29 | 1985-09-24 | Colorcon, Inc. | Dry edible film coating composition, method and coating form |
US4316897A (en) | 1980-09-10 | 1982-02-23 | Hoffmann-La Roche Inc. | Method of lowering serum prolactin |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
JP3696884B2 (en) | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | Enhancement of drug efficacy by deuteration |
CA2227410A1 (en) | 1995-07-24 | 1997-02-06 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
GB9817028D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
US7260823B2 (en) | 2001-01-11 | 2007-08-21 | Prime Research Alliance E., Inc. | Profiling and identification of television viewers |
US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
ES2193921T3 (en) | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | SULFAMOILHETEROARIL-PIRAZOL COMPOUNDS AS ANTINFLAMATORY / ANALGESIC AGENTS. |
EP1134290A3 (en) | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
US20020183553A1 (en) | 2000-10-19 | 2002-12-05 | Ben-Zion Dolitzky | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
MXPA04005305A (en) | 2001-12-05 | 2004-09-13 | Wyeth Corp | Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof. |
TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
EP2535042A1 (en) | 2003-06-16 | 2012-12-19 | ANDRX Pharmaceuticals LLC. | Oral sustained-release composition comprising a macrolide |
AU2004292966A1 (en) | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
US7367953B2 (en) | 2003-11-26 | 2008-05-06 | Ge Medical Systems Global Technology Company | Method and system for determining a period of interest using multiple inputs |
US20100018408A1 (en) | 2004-02-06 | 2010-01-28 | Lassota Zbigniew G | Brew basket assembly and brewer |
GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
EP1750717B1 (en) | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
MX2007007189A (en) | 2005-01-19 | 2010-09-28 | Rigel Pharmaceuticals Inc | Prodrugs of 2,4-pyrimidinediamine compounds and their uses. |
JP5199678B2 (en) | 2005-02-23 | 2013-05-15 | プレクサ ファーマシューティカルズ, インコーポレイテッド | Dopamine transporter inhibitors for use in the treatment of movement disorders and other CNS indications |
AU2006261893A1 (en) | 2005-06-23 | 2007-01-04 | Combinatorx, Incorporated | Improved dosage forms for movement disorder treatment |
US20080033011A1 (en) | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
UA97795C2 (en) | 2006-02-17 | 2012-03-26 | Бьордз Фарма Гмбх Бероліна Інновейтів Ресерч Унд Девелопмент Сервісіз | Deuterated catecholamine derivatives and medicaments comprising said compounds |
SI2012833T1 (en) | 2006-05-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Radiolabeled dihydrotrabenazine derivatives and their use as imaging agents |
HU227610B1 (en) | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
MX2009003743A (en) | 2006-10-12 | 2009-06-18 | Novartis Ag | Use of modified cyclosporins. |
KR101500766B1 (en) | 2006-11-08 | 2015-03-16 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol Compounds and Methods Relating Thereto |
ATE540041T1 (en) | 2006-11-21 | 2012-01-15 | Rigel Pharmaceuticals Inc | PRODRUG SALTS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES THEREOF |
WO2008112278A2 (en) | 2007-03-12 | 2008-09-18 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
DK2125698T3 (en) | 2007-03-15 | 2016-11-07 | Auspex Pharmaceuticals Inc | Deuterated d9-VENLAFAXINE |
US7897768B2 (en) | 2007-06-08 | 2011-03-01 | General Electric Company | Method for making tetrabenazine compounds |
CA2729006C (en) | 2007-06-29 | 2017-01-31 | Clarencew Pty Ltd | Treatment or prophylaxis of neurological or neuropsychiatric disorders via ocular administration |
US8053578B2 (en) | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
US7902364B2 (en) | 2007-11-29 | 2011-03-08 | General Electric Company | Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
WO2009124357A1 (en) | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
WO2009126305A1 (en) | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University | Glucose metabolism modulating compounds |
JP5207852B2 (en) | 2008-06-30 | 2013-06-12 | 三洋電機株式会社 | Solar cell and manufacturing method thereof |
WO2010002972A1 (en) | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US20100018969A1 (en) | 2008-07-24 | 2010-01-28 | Feature Foods, Inc. | Packaging for food products |
US20110053866A1 (en) | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
EP3061760B1 (en) | 2008-09-18 | 2017-11-08 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
US20100113496A1 (en) | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
EP2396312A1 (en) | 2009-02-11 | 2011-12-21 | Celgene Corporation | Isotopologues of lenalidomide |
CA2771539A1 (en) * | 2009-08-12 | 2011-02-17 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenzine |
US8658236B2 (en) | 2009-08-21 | 2014-02-25 | Deuteria Beverages, Llc | Alcoholic compositions having a lowered risk of acetaldehydemia |
KR20120120970A (en) | 2010-02-24 | 2012-11-02 | 오스펙스 파마슈티칼스, 인코포레이티드 | Trimethoxyphenyl inhibitors of tyrosine kinase |
US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
AU2011261551B2 (en) * | 2010-06-01 | 2016-10-20 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of VMAT2 |
US9321095B2 (en) | 2010-06-30 | 2016-04-26 | General Electric Company | Apparatuses and methods for cutting porous substrates |
US9676810B2 (en) | 2010-07-08 | 2017-06-13 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
AU2011298382A1 (en) | 2010-09-03 | 2013-05-02 | Teva Pharmaceuticals International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
WO2012081031A1 (en) | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
RU2017124629A (en) | 2011-01-20 | 2019-01-30 | Бионевиа Фармасьютикалс Инк. | COMPOSITIONS WITH MODIFIED RELEASE OF EPALRESTAT OR ITS DERIVATIVES AND METHODS FOR USING THEM |
WO2012100202A1 (en) | 2011-01-22 | 2012-07-26 | Filippo Costanzo | Dynamic 2d and 3d gestural interfaces for audio video players capable of uninterrupted continuity of fruition of audio video feeds |
CA2839481A1 (en) | 2011-06-24 | 2012-12-27 | The Directv Group, Inc. | Method and system for obtaining viewing data and providing content recommendations at a set top box |
US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
KR101362482B1 (en) | 2012-01-31 | 2014-02-12 | 한국과학기술연구원 | Preparation of tetrabenazine and dihydrotetrabenazine |
EP2827856A4 (en) | 2012-03-23 | 2016-03-09 | Cardero Therapeutics Inc | Compounds and compositions for the treatment of muscular disorders |
WO2014047167A1 (en) * | 2012-09-18 | 2014-03-27 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
CN102936246A (en) | 2012-11-08 | 2013-02-20 | 江苏暨明医药科技有限公司 | Method for synthesizing tetrabenazine |
EP2951178A4 (en) | 2013-01-31 | 2016-07-06 | Auspex Pharmaceuticals Inc | Benzoquinolone inhibitors of vmat2 |
US20160207917A1 (en) | 2013-09-27 | 2016-07-21 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
WO2015077521A1 (en) | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
US20160303110A1 (en) | 2013-11-22 | 2016-10-20 | Auspex Pharmaceuticals, Inc. | Methods of treating abnormal muscular activity |
WO2015084622A1 (en) | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
US20160346270A1 (en) | 2014-01-27 | 2016-12-01 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
EA201691582A1 (en) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | NEW PHARMACEUTICAL PREPARATIONS |
CN107624067A (en) | 2015-03-06 | 2018-01-23 | 奥斯拜客斯制药有限公司 | Method for treating Abnormal involuntary movement obstacle |
CN117915901A (en) * | 2021-04-15 | 2024-04-19 | 纽罗克里生物科学有限公司 | Combined administration method of deutetrabenazine and CYP2D6 inhibitor |
-
2016
- 2016-03-07 CN CN201680026246.3A patent/CN107624067A/en active Pending
- 2016-03-07 PT PT167117332T patent/PT3265085T/en unknown
- 2016-03-07 KR KR1020177027769A patent/KR102335744B1/en active IP Right Grant
- 2016-03-07 EP EP16711733.2A patent/EP3265085B1/en active Active
- 2016-03-07 WO PCT/US2016/021238 patent/WO2016144901A1/en active Application Filing
- 2016-03-07 RS RS20220911A patent/RS63647B1/en unknown
- 2016-03-07 CN CN202210050644.6A patent/CN114767672A/en active Pending
- 2016-03-07 CN CN202210050163.5A patent/CN114788824A/en active Pending
- 2016-03-07 IL IL305352A patent/IL305352A/en unknown
- 2016-03-07 CA CA2978006A patent/CA2978006C/en active Active
- 2016-03-07 PL PL16711733.2T patent/PL3265085T3/en unknown
- 2016-03-07 SG SG11201706959TA patent/SG11201706959TA/en unknown
- 2016-03-07 ES ES16711733T patent/ES2927262T3/en active Active
- 2016-03-07 IL IL288712A patent/IL288712B2/en unknown
- 2016-03-07 JP JP2017546819A patent/JP6932641B2/en active Active
- 2016-03-07 MX MX2017011459A patent/MX2017011459A/en unknown
- 2016-03-07 CN CN202210050199.3A patent/CN114796209A/en active Pending
- 2016-03-07 KR KR1020217039416A patent/KR102528845B1/en active IP Right Grant
- 2016-03-07 DK DK16711733.2T patent/DK3265085T3/en active
- 2016-03-07 HU HUE16711733A patent/HUE059747T2/en unknown
- 2016-03-07 EA EA201791977A patent/EA201791977A1/en unknown
- 2016-03-07 EP EP22185826.9A patent/EP4140483A1/en active Pending
- 2016-03-07 KR KR1020227042661A patent/KR20230003264A/en not_active IP Right Cessation
- 2016-03-07 US US15/063,068 patent/US20160287574A1/en not_active Abandoned
- 2016-03-07 KR KR1020247010755A patent/KR20240049625A/en active Application Filing
- 2016-03-07 HR HRP20221106TT patent/HRP20221106T1/en unknown
- 2016-03-07 CA CA3236214A patent/CA3236214A1/en active Pending
- 2016-03-07 LT LTEPPCT/US2016/021238T patent/LT3265085T/en unknown
- 2016-03-07 AU AU2016229949A patent/AU2016229949B2/en active Active
-
2017
- 2017-02-09 US US15/428,868 patent/US20170151227A1/en not_active Abandoned
- 2017-08-02 US US15/667,483 patent/US11648244B2/en active Active
- 2017-08-23 IL IL254121A patent/IL254121B/en unknown
- 2017-09-01 CL CL2017002223A patent/CL2017002223A1/en unknown
- 2017-09-06 MX MX2021009830A patent/MX2021009830A/en unknown
- 2017-09-08 ZA ZA2017/06131A patent/ZA201706131B/en unknown
- 2017-10-02 US US15/722,208 patent/US11564917B2/en active Active
-
2018
- 2018-07-04 HK HK18108643.4A patent/HK1248609A1/en unknown
- 2018-07-19 HK HK18109350.5A patent/HK1249860A1/en unknown
- 2018-07-19 US US16/040,012 patent/US10959996B2/en active Active
-
2019
- 2019-04-04 ZA ZA2019/02108A patent/ZA201902108B/en unknown
-
2021
- 2021-01-21 US US17/154,312 patent/US11357772B2/en active Active
- 2021-03-25 US US17/212,205 patent/US11446291B2/en active Active
- 2021-07-07 AU AU2021204740A patent/AU2021204740A1/en active Pending
- 2021-08-12 US US17/400,194 patent/US12016858B2/en active Active
- 2021-08-17 JP JP2021132745A patent/JP7066902B2/en active Active
-
2022
- 2022-04-26 JP JP2022072345A patent/JP2022109989A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288712A (en) | Methods for the treatment of abnormal involuntary movement disorders | |
IL285151B1 (en) | Methods of treating fgf21-associated disorders | |
HK1231417A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
IL267229A (en) | Methods of treating ocular disorders | |
SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
HK1250624A1 (en) | Methods for the treatment of cardiovascular disorders | |
GB201602784D0 (en) | New treatment of CFTR-related disorders | |
GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201506419D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201506229D0 (en) | Methods For the Treatment Of Inflammatory Disorders | |
GB201506228D0 (en) | Methods For The Treatment Of Cardivascular Disorders | |
GB201521542D0 (en) | Methods for the treatment of cardiovascular disorders | |
GB201513991D0 (en) | Methods for the treatment of cardiovascular disorders | |
GB201513344D0 (en) | Methods for the treatment of Cardiovascular disorders | |
GB201507109D0 (en) | Methods for the treatment of cardiovascular disorders | |
GB201413533D0 (en) | Combination therapy for treating disorders of the vestibular system |